News
RPRX
27.98
+0.58%
0.16
Weekly Report: what happened at RPRX last week (0415-0419)?
Weekly Report · 3d ago
ROYALTY PHARMA TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9, 2024
Reuters · 5d ago
Royalty Pharma declares $0.21 dividend
Seeking Alpha · 04/17 12:17
Press Release: Royalty Pharma Declares Second Quarter 2024 Dividend
Royalty Pharma plc has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024. Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation.
Dow Jones · 04/17 12:15
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
NASDAQ · 04/15 10:20
Weekly Report: what happened at RPRX last week (0408-0412)?
Weekly Report · 04/15 09:01
Relative Strength Alert For Royalty Pharma
NASDAQ · 04/12 15:59
Royalty Pharma Price Target Cut to $38.00/Share From $40.00 by B of A Securities
Dow Jones · 04/12 12:11
Royalty Pharma Is Maintained at Buy by B of A Securities
Dow Jones · 04/12 12:11
B of A Securities Maintains Buy on Royalty Pharma, Lowers Price Target to $38
Benzinga · 04/12 12:01
ROYALTY PHARMA <RPRX.O>: BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $38 FROM $40
Reuters · 04/12 10:16
ROYALTY PHARMA PLC <RPRX.O>: MORGAN STANLEY RAISES TARGET PRICE TO $46.00 FROM $44.00
Reuters · 04/10 14:48
Weekly Report: what happened at RPRX last week (0401-0405)?
Weekly Report · 04/08 09:01
Looking Into Royalty Pharma's Recent Short Interest
Royalty Pharma's short percent of float has fallen 3.91% since its last report. The company has 12.65 million shares sold short, which is 2.95% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/04 15:15
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Royalty Pharma plc (NASDAQ:RPRX) has US$6.14b of debt on its balance sheet. The company uses debt to fund growth, but is this a concern for shareholders? Royalty Pharma has a debt to EBITDA ratio of 3.8. The balance sheet is a good place to look at to see if a company can manage its debt. Royalty Pharmaceutical's debt is covered by its free cash flow, but its interest cover is low.
Simply Wall St · 04/04 15:07
January 2025 Options Now Available For Royalty Pharma (RPRX)
NASDAQ · 04/03 14:39
Cytokinetics, Incorporated: Buyout Speculation Persists
Cytokinetics, Incorporated has seen persistent buyout speculation in recent months. The company's stock has been linked to Eli Lilly, Novartis, Amgen, and AstraZeneca as potential suitors for the company. Cytokinetic's aficamten, a treatment for heart disease, showed promising results in a Phase 3 study. The drug is set for potential FDA approval in 2025 and is expected to generate $4 billion in sales. The stock has a strong balance sheet and positive analyst ratings.
Seeking Alpha · 04/01 10:08
Weekly Report: what happened at RPRX last week (0325-0329)?
Weekly Report · 04/01 09:01
Ford, Envista Holdings, and Alaska Air are among additions to GS’ Short Duration list
Ford, Envista Holdings, and Alaska Air are among additions to GS’ Short Duration list. Goldman Sachs analysts published their rebalanced list for their ‘short duration’ basket. The basket returned 3% year-to-date, compared to 6% for the equal-weight S&P 500.
Seeking Alpha · 03/28 17:49
Weekly Report: what happened at RPRX last week (0318-0322)?
Weekly Report · 03/25 09:01
More
Webull provides a variety of real-time RPRX stock news. You can receive the latest news about Royalty Pharma Plc through multiple platforms. This information may help you make smarter investment decisions.
About RPRX
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.